Anti-inflammatory treatments for stroke: from bench to bedside

被引:63
|
作者
Drieu, Antoine [1 ]
Levard, Damien [1 ]
Vivien, Denis [1 ,2 ]
Rubio, Marina [1 ]
机构
[1] Normandy Univ, Pathophysiol & Imaging Neurol Disorders, Blvd Henri Becquerel BP 5229, F-14000 Caen, France
[2] CHU Caen, Imaging Neurol Disorders, Caen, France
关键词
clinical trial; immunomodulatory drugs; inflammation; stroke models; translation; ACUTE ISCHEMIC-STROKE; REGULATORY T-CELLS; FOCAL CEREBRAL-ISCHEMIA; SPINAL-CORD-INJURY; INTERLEUKIN-1 RECEPTOR ANTAGONIST; IMMUNE MODULATOR FINGOLIMOD; SENSITIVE MOLECULAR MRI; CENTRAL-NERVOUS-SYSTEM; REDUCES BRAIN-DAMAGE; THROMBOEMBOLIC STROKE;
D O I
10.1177/1756286418789854
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
So far, intravenous tissue-type plasminogen activator (tPA) and mechanical removal of arterial blood clot (thrombectomy) are the only available treatments for acute ischemic stroke. However, the short therapeutic window and the lack of specialized stroke unit care make the overall availability of both treatments limited. Additional agents to combine with tPA administration or thrombectomy to enhance efficacy and improve outcomes associated with stroke are needed. Stroke-induced inflammatory processes are a response to the tissue damage due to the absence of blood supply but have been proposed also as key contributors to all the stages of the ischemic stroke pathophysiology. Despite promising results in experimental studies, inflammation-modulating treatments have not yet been translated successfully into the clinical setting. This review will (a) describe the timing of the stroke immune pathophysiology; (b) detail the immune responses to stroke sift-through cell type; and (c) discuss the pitfalls on the translation from experimental studies to clinical trials testing the therapeutic pertinence of immune modulators.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] From the bench to the bedside: emerging new treatments in multiple myeloma
    Hayden, Patrick J.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    [J]. TARGETED ONCOLOGY, 2008, 3 (01) : 19 - 29
  • [22] From the bench to the bedside: emerging new treatments in multiple myeloma
    Patrick J. Hayden
    Constantine S. Mitsiades
    Kenneth C. Anderson
    Paul G. Richardson
    [J]. Targeted Oncology, 2008, 3 : 19 - 29
  • [23] From the bench to the bedside: emerging new treatments in multiple myeloma
    Mitsiades, Constantine S.
    Hayden, Patrick J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 797 - 816
  • [24] Cholinergic Anti-inflammatory Pathway and Stroke
    Duris, Kamil
    Lipkova, Jolana
    Jurajda, Michal
    [J]. CURRENT DRUG DELIVERY, 2017, 14 (04) : 449 - 457
  • [25] Urticaria: "From bench to bedside" [Urtikaria: "From bench to bedside"]
    Magerl M.
    Maurer M.
    [J]. Der Hautarzt, 2007, 58 (4): : 308 - 313
  • [26] Peritoneal dialysis: from bench to bedside and bedside to bench
    Perl, Jeffrey
    Bargman, Joanne M.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 311 (05) : F999 - F1004
  • [27] Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
    Pelliccia, Francesco
    Morgantini, Amalia
    Rosati, Riccardo
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [28] Potential anti-inflammatory treatments for chronic wounds
    McKelvey, K.
    Xue, M.
    Whitmont, K.
    Shen, K.
    Cooper, A.
    Jackson, C.
    [J]. WOUND PRACTICE AND RESEARCH, 2012, 20 (02): : 86 - 89
  • [29] Anti-inflammatory treatments in sepsis - Comment - Reply
    Reinhart, K
    Bloos, F
    [J]. CHIRURG, 2003, 74 (06): : 591 - 592
  • [30] Clinical studies and anti-inflammatory mechanisms of treatments
    French, Jacqueline A.
    Koepp, Matthias
    Naegelin, Yvonne
    Vigevano, Federico
    Auvin, Stephane
    Rho, Jong M.
    Rosenberg, Evan
    Devinsky, Orrin
    Olofsson, Peder S.
    Dichter, Marc A.
    [J]. EPILEPSIA, 2017, 58 : 69 - 82